Global Down Syndrome

Winter 2015

Issue link: https://viewer.e-digitaledition.com/i/459868

Contents of this Issue

Navigation

Page 13 of 31

WINTER2015 DOWN SYNDROME WORLD 14 WELCOME TO POINT/ COUNTERPOINT. Each issue, key representatives from the Down syndrome community will address two sides of an important yet controversial issue. Down Syndrome World is not taking a stand on these issues but rather presenting information so our readers can further investigate and come to their own conclusions. We are fortunate to have two esteemed experts weigh in on the issue. They have written independently of each other, and we thank them for their time and opinions. CON William C. Mobley, M.D., Ph.D., is a Distinguished Professor and Chair of the Department of Neurosciences at the University of California, San Diego. He also serves as Executive Director of UCSD's Down Syndrome Center for Research and Treatment and as Florence Riford Chair of Alzheimer's Disease Research. Just 10 years ago, treatments focused on improving cognition in people with Down syndrome were only an aspiration. Today, thanks to investments by various foundations and the National Institutes of Health, we can expect increased testing and, hopefully, discovery of effective treatments. One important treatment approach to improve cognition is drug discovery. Scientists follow a strict code of ethical conduct that is further enforced by legislation: Drug discovery and testing must be under the supervision of the U.S. Food and Drug Administration; there should be results in animal models before testing humans; and human studies and clinical trials must have Institutional Review Board approval to protect the rights and welfare of those who agree to be tested. My own work in mouse models of Down syndrome shows that cognitive performance is rescued using antagonists of GABA B receptors as well as drugs that enhance norepinephrine levels. This provides early ideas for targets and drugs but certainly does not prove they would work in people with Down syndrome. Well-meaning parents have decided to experiment using drugs that target GABA A and other brain targets by creating a cocktail of drugs (including Prozac, Ginkgo biloba, and Focalin). My training and experience shows that this is not acceptable. Such cocktails could be unsafe as well as ineffective. I would urge the entire Down syndrome community to avoid participating in such activities. Scientists are working hard toward improving cognition in people with Down syndrome. We believe the safety of the individual must be the highest priority. As such, we would strongly discourage the use of so-called cognition-enhancing drugs until they have been proven safe and effective. Learn more at www.down-syndrome.org/statements/2106/. SHOULD PARENTS USE AN UNTESTED MIX OF MEDICATIONS AFFECTING THE BRAIN CHEMISTRY OF THEIR CHILDREN WITH DOWN SYNDROME IN HOPES OF IMPROVING COGNITION? Point/Counterpoint PRO Teresa Cody, D.D.S, is founder of the Changing Minds Foundation in Richmond, Texas, whose mission is to spread awareness that treatment is available for many of the problems and symptoms associated with Down syndrome. Treatment for Down syndrome is about balancing brain chemistry. Balancing brain chemistry is exactly what psychiatric medicine is today. At one time, you went to the doctor to talk about your problems. Now, you describe a symptom and are given a prescription to balance the chemistry. It may take some trial and error, and that is where we are fortunate. Researchers have a mouse model that can help explain what is going on inside the brains of people with Down syndrome. An argument against treatment is that there have not been clinical trials using psychiatric agents specifically on individuals with Down syndrome. Actually, there have not been Down syndrome-specific clinical trials using any medicine commonly given to individuals with Down syndrome. We use antibiotics, reflux medicine, ibuprofen, and cough medicine — has anyone demanded a clinical trial using any of these medicines? We assume that the person with Down syndrome is similar enough to the average person to safely use them. The source of slow processing, low motor skills, low verbal skills, and poor memory is in the brain. Only when we move to treat the brain is a clinical trial brought up. It would be fantastic if there were clinical trials, but it has been 10 years since we first learned the causes of the disabilities. Balancing brain chemistry is not new. We now understand how friends and loved ones struggling with depression can be helped with the correct medicine. The situation in Down syndrome is exactly the same thing; it is a matter of balancing brain chemistry to proper levels. Learn more at changingmindsfoundation.org.

Articles in this issue

Links on this page

Archives of this issue

view archives of Global Down Syndrome - Winter 2015